|View printer-friendly version|
Selecta Biosciences Announces Second Quarter 2016 Financial Results and Provides Corporate Update
- Demonstrated clinical activity in Phase 1 program of SEL-212
- Advanced two proprietary gene therapy programs based on the same SVP-Rapamycin immunotherapy as SEL-212
- Successfully completed Initial Public Offering with net proceeds of
$64.5 million, including proceeds from the exercise of the underwriters’ option to purchase additional stock
- At the end of the second quarter of 2016,
Selectahad cash, cash equivalents, investments and restricted cash of $85.3 million
“We have made significant progress this year to advance our SVP™ platform in antigen-specific tolerance, demonstrating clinical activity in the Phase 1 program of our lead program SEL-212 for refractory and tophaceous gout, and securing collaborators and resources to advance our differentiated gene therapy programs toward the clinic. In addition, we completed a successful initial public offering of our common stock, which gives us the financial runway to advance and expand our pipeline, and, we believe, indicates confidence in our science, our team and our data to date,” said
Second Quarter and Recent Business Highlights:
- Progressing with Lead Program SEL-212 in Gout: The objectives of the Phase 1a/b program in patients with hyperuricemia were achieved by identifying clinically active doses of SEL-212 (SVP-Rapamycin plus pegsiticase), and by identifying a maximum tolerated dose of the product candidate. The role of SVP-Rapamycin in the SEL-212 product candidate is to induce antigen-specific tolerance against the uricase enzyme. In the Phase 1a single ascending dose trial of pegsiticase only (without SVP-Rapamycin), antibodies against the uricase enzyme were formed as expected, curtailing control of uric acid in many patients to no more than 14 days. It is notable that up to 92% of patients treated with a currently marketed version of uricase for gout also develop immune responses, which have been linked to reduced efficacy and safety. Data from the ongoing Phase 1b single ascending dose trial of SVP-Rapamycin plus fixed doses of pegsiticase demonstrate that clinically active doses of SEL-212 are well tolerated and can prevent the formation of antibodies against the uricase enzyme, enabling sustained control of uric acid for at least 30 days after a single dose, supporting monthly dosing in the upcoming Phase 2 trial. At a dose level 65% above the maximum tolerated dose and 5 times above a clinically active dose of SEL-212, two serious adverse events of stomatitis, a known side effect of rapamycin, occurred and resolved without issues. The second of these two cases was initially diagnosed as a sore throat and graded as a non-serious adverse event, but was retrospectively reclassified in
July 2016by the investigator of that subject. Presentation of the clinical data from the Phase 1a and 1b trials is planned at a scientific meeting in the second half of 2016.
Preparations of the Phase 2 trial of SEL-212 in symptomatic gout patients with hyperuricemia remain on track for initiation during the second half of 2016. This study is expected to be conducted at approximately 15 centers across
- Advancing Gene Therapy Programs:
Selectaalso announced plans to focus its first two gene therapy programs to be developed with the proprietary immunotherapeutic candidate SVP-Rapamycin for two rare genetic disorders of metabolism, Methylmalonic Acidemia (MMA) and Ornithine Transcarbamylase Deficiency (OTC). Both diseases cause severe developmental issues and lack effective treatments. SVP-Rapamycin has been shown to inhibit antibody responses to AAV vector and has enabled repeat dosing in animals by our collaborator, Dr. Federico Mingozziof Genethon. Mitigation of undesired immune responses associated with gene therapy vectors would enable earlier and more frequent treatment, which could result in better therapeutic outcomes compared to gene therapies without SVP-Rapamycin.
- Achieved Milestone Payment under Collaboration with
Sanofi: Selecta’s two programs with Sanofifor a food allergy and celiac disease continue to progress. In the second quarter of 2016, Selectaachieved a milestone in the celiac disease program leading to a $1 millionpayment. Under the terms of the collaboration with Sanofi, Selectais eligible to receive research support and milestones totaling up to $300 millionfor each program. Additionally, Selectais entitled to up to double-digit tiered royalties as a percentage of product net sales for any commercialized immunotherapy resulting from these efforts with Sanofi.
- Published research on mechanism and application potential in Nature Nanotechnology: Preclinical data has recently been published in Nature Nanotechnology supporting Selecta’s lead clinical program, showing that Selecta’s SVP-Rapamycin induces antigen-specific immune tolerance and mitigates the formation of anti-drug antibodies (ADAs) to biologic drugs, including pegsiticase (for gout) and adalimumab (for rheumatoid arthritis). It was demonstrated that once tolerance is induced in mice and cynomolgus monkey, the biologic drug could be administered without the SVP-Rapamycin while avoiding subsequent formation of ADAs. The publication elucidates the mechanisms by which SVP-Rapamycin induces tolerance to mitigate the immunogenicity of biologics including induction of tolerogenic dendritic cells; increase in regulatory T cells; reduction in B cell activation and germinal center formation; and inhibition of antigen-specific hypersensitivity reactions.
- Successfully Completed Initial Public Offering: In June 2016,
Selectacompleted its initial public offering of common stock, raising net proceeds of $60.8 million, after deducting underwriting discounts and commissions and offering expenses. In July 2016, Selectareceived additional proceeds of $3.7 million, after deducting underwriting discounts, commissions and offering expenses, from the exercise in part of the underwriters’ overallotment option.
- Announced Board Appointments:
Selectaappointed Timothy C. Barabeto its Board of Directors and Audit Committee. Mr. Barabe has extensive experience in the life sciences industry and serves on the Boards of Directors of Arqule, Vigilant Biosciences, Veeva Systemsand Opexa Therapeutics. Mr. Barabe retired in June 2013from his position as Executive Vice President and Chief Financial Officer of Affymetrix, Inc.Previously, he was Senior Vice President and Chief Financial Officer of Human Genome Sciences and Regent Medical Limitedand served with Novartis AGfrom 1982 through 2004 in a succession of senior executive positions in finance and general management, most recently as the Chief Financial Officer of Sandoz GmbH.
Unaudited Second Quarter Financial Results:
- Net Loss: For the second quarter of 2016,
Selectareported a net loss of $6.9 million, or $(2.75)per share, compared to a net loss of $6.9 million, or $(3.93)per share, for the same period in 2015.
- Revenue: For the second quarter of 2016, total revenue of
$2.0 millionincreased by $0.8 millionas compared to the same period in the prior year, of which $0.7 millionwas related to a National Institute of Drug Abusegrant, and $0.3 millionwas from other grants, offset by $0.2 millionlower revenue from collaborations based on the timing of the company’s research efforts.
- Research and Development Expenses: Research and development expenses for the second quarter of 2016 of
$6.0 millionincreased by $0.7 millionas compared to the same period in the prior year. The increase is primarily related to the SEL-212 clinical program, expenses associated with research grants and stock compensation expense, offset by a reduction in license fees.
- General and Administrative Expenses: General and administrative expenses of
$2.4 millionfor the second quarter of 2016, increased by $0.2 millioncompared to the same period in the prior year, primarily due to an increase in patent costs and an increase in accounting fees for quarterly reviews of the company’s financial statements, offset by lower depreciation.
- Cash Position:
Selectahad cash, cash equivalents, investments and restricted cash of $85.3 millionat June 30, 2016. In July 2016, Selectareceived additional net proceeds of $3.7 millionfrom the exercise in part of the underwriters’ over-allotment option.
- Financial Guidance: Based on the current operating plan,
Selectaexpects that its cash, cash equivalents, investments and restricted cash as of June 30, 2016, will fund operating expenses and capital expenditure requirements into the first quarter of 2018.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the impact of our initial public offering on our financial position and development of our pipeline, the timing of the Phase 2 clinical trial of SEL-212, including initiation, announcement of data, conference presentations, the number of centers in the Phase 2 clinical trial of SEL-212, the ability of our SVP platform, including SVP-Rapamycin, to mitigate immune response and create better therapeutic outcomes, the potential treatment applications for SVP products, and the sufficiency of our cash, cash equivalents, investments, and restricted cash.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have incurred significant losses and may never become profitable; our need for additional funding, which may not be available; our limited operating history; operating and financial restrictions from our credit facility and the charter of our Russian subsidiary; limitations on our ability to use our net operating loss and research and development tax credit carryforwards; the early stage of clinical development for our product candidates; the unproven approach of our SVP technology; our failure to capitalize on more profitable candidates or indications; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; potential delays in regulatory approval, which would impact the ability to commercialize our product candidates and affect our ability to generate revenue; our potential inability to obtain orphan drug designation; any fast track or Breakthrough Therapy designation may not lead to faster development, or regulatory or marketing approval; undesirable side effects of our product candidates, which could negatively impact regulatory approval or commercialization; our reliance on third parties to manufacture our product candidates and to conduct our clinical trials; our inability to maintain our existing or future collaborations or licenses; our lack of experience in manufacturing our product candidates on a commercial scale; failure of our product candidates to achieve market acceptance; our inability to establish effective sales, marketing and distribution capabilities; failure of our product candidates to offer material commercial advantages over other treatments; failure to compete successfully against other drug companies; unfavorable pricing regulations, third-party coverage, or reimbursement policies; product liability lawsuits; failure to obtain marketing approval internationally; compliance with healthcare laws and regulations; recently enacted or future legislation; post-marketing restrictions or withdrawal from the market; compliance with export and import controls, sanctions, embargoes, anti-corruption and anti-money laundering laws and regulations; strict price controls imposed by foreign governments; compliance with environmental, health, and safety laws and regulations; negative public opinion or increased regulatory scrutiny of gene therapy and genetic research; our inability to protect our proprietary technology and intellectual property; our inability to protect the confidentiality of our trade secrets and know-how; changes in
These and other important factors discussed under the caption “Risk Factors” in our final prospectus filed with the
|Selecta Biosciences, Inc. and Subsidiaries|
|Consolidated Balance Sheets|
|(In thousands, except for shares and par value)|
|June 30,||December 31,|
|Cash and cash equivalents||$||82,648||$||32,337|
|Short term deposits and investments||1,900||4,125|
|Prepaid expenses and other current assets||2,131||1,494|
|Total current assets||89,047||38,913|
|Property and equipment, net||1,954||2,029|
|Restricted cash and other deposits||316||316|
|Liabilities, redeemable convertible preferred stock, and stockholders’ deficit|
|Loans payable, current portion||1,781||—|
|Deferred revenue, current portion||1,242||1,313|
|Contingently repayable grant funding||258||420|
|Total current liabilities||8,939||7,290|
|Deferred rent and lease incentive||—||105|
|Loans payable, net of current portion||10,128||11,855|
|Deferred revenue, net of current portion||3,474||2,295|
|Other long‑term liabilities||—||290|
|Commitments and contingencies (Notes 7 and 12)|
|Redeemable Convertible Preferred Stock:|
|Series A redeemable convertible preferred stock, $0.0001 par value; 0 and 2,589,868 shares authorized; 0 and
2,589,868 shares issued and outstanding; as of June 30, 2016 and December 31, 2015 respectively.
|Series B redeemable convertible preferred stock, $0.0001 par value; 0 and 7,437,325 shares authorized; 0 and
7,437,325 shares issued and outstanding; as of June 30, 2016 and December 31, 2015 respectively.
|Series C redeemable convertible preferred stock, $0.0001 par value; 0 and 5,000,002 shares authorized; 0 and
5,000,002 shares issued and outstanding; as of June 30, 2016 and December 31, 2015 respectively.
|Series D redeemable convertible preferred stock, $0.0001 par value; 0 and 8,166,662 shares authorized; 0 and
8,099,994 shares issued and outstanding; as of June 30, 2016 and December 31, 2015 respectively.
|Series SRN redeemable convertible preferred stock, $0.0001 par value; 0 and 5,611,112 shares authorized; 0 and
2,111,109 shares issued and outstanding; as of June 30, 2016 and December 31, 2015 respectively.
|Series E redeemable convertible preferred stock, $0.0001 par value; 0 and 9,030,654 shares authorized; 0 and
8,888,888 shares issued and outstanding; as of June 30, 2016 and December 31, 2015 respectively.
|Total redeemable convertible preferred stock||—||137,482|
|Stockholders’ equity (deficit):|
|Preferred Stock, $0.0001 par value; 10,000,000 and 0 shares authorized; 0 and 0 shares issued and outstanding at
June 30, 2016 and December 31, 2015, respectively.
|Common stock, $0.0001 par value; 200,000,000 and 62,164,377 shares authorized at June 30, 2016 and
December 31, 2015 respectively; 17,900,547 and 2,180,976 shares issued, 17,895,824 and 2,173,399 shares
outstanding as of June 30, 2016 and December 31, 2015, respectively
|Additional paid-in capital||203,125||1|
|Accumulated other comprehensive loss||(4,585||)||(4,986||)|
|Total stockholders’ equity (deficit)||68,776||(116,493||)|
|Total liabilities, redeemable convertible preferred stock and stockholders’ equity||$||91,317||$||42,824|
|Selecta Biosciences, Inc. and Subsidiaries|
|Consolidated Statements of Operations and Comprehensive Loss|
|(Unaudited, amounts in thousands, except share and per share data)|
|Three Months Ended June 30,|
|Grant and collaboration revenue||$||2,017||$||1,236|
|Research and development||6,000||5,314|
|General and administrative||2,418||2,238|
|Total operating expenses||8,418||7,552|
|Loss from operations||(6,401||)||(6,316||)|
|Foreign currency transaction gain (loss), net||(158||)||(246||)|
|Other expense, net||(64||)||(37||)|
|Other comprehensive loss:|
|Foreign currency translation adjustment||170||245|
|Accretion of redeemable convertible preferred stock||(2,210||)||(1,562||)|
|Net loss attributable to common stockholders||$||(9,133||)||$||(8,429||)|
|Net loss per share attributable to common stockholders|
|Basic and diluted||$||(2.75||)||$||(3.93||)|
|Weighted average common shares outstanding|
|Basic and diluted||3,322,546||2,147,184|
Kathryn MorrisThe Yates Network +1-845-635-9828 email@example.com Investor contact: Stephanie AscherStern Investor Relations, Inc. +1-212-362-1200 firstname.lastname@example.org